KalVista Pharmaceuticals (NASDAQ:KALV) Issues Earnings Results

KalVista Pharmaceuticals (NASDAQ:KALV) issued its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.29), Yahoo Finance reports.

KalVista Pharmaceuticals Stock Performance

Shares of KALV stock opened at $13.04 on Friday. The firm’s 50 day moving average is $11.86 and its 200 day moving average is $12.45. KalVista Pharmaceuticals has a 12 month low of $7.21 and a 12 month high of $16.88.

Insider Activity at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 21,959 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.76, for a total transaction of $258,237.84. Following the sale, the chief executive officer now directly owns 216,387 shares in the company, valued at approximately $2,544,711.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Benjamin L. Palleiko sold 21,959 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.76, for a total transaction of $258,237.84. Following the sale, the chief executive officer now directly owns 216,387 shares in the company, valued at approximately $2,544,711.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 7,465 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $11.53, for a total transaction of $86,071.45. Following the sale, the chief executive officer now owns 224,547 shares in the company, valued at $2,589,026.91. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,512 shares of company stock worth $439,424. 12.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

KALV has been the subject of a number of recent analyst reports. HC Wainwright reduced their price objective on shares of KalVista Pharmaceuticals from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, May 3rd. Needham & Company LLC dropped their target price on shares of KalVista Pharmaceuticals from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Friday.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.